Elos Medtech - Interim report, 1 January – 30 September 2016
Continued improved earnings and strong cash flow• Net sales increased to SEK 418.7 M (367.7) which, adjusted for exchange-rate fluctuations, corresponds to a rise of 14.7%, of which organic growth was 2.1%. • Operating profit improved to SEK 39.7 M (25.5, adjusted for non-recurring items of 34.0). • Profit after net financial items totalled SEK 32.1 M (20.0). Net financial items were positively affected by exchange-rate differences of SEK 1.1 M (0.1). • Profit after tax amounted to SEK 23.5 M (12.9), corresponding to SEK 3.88 (2.13) per share. • Cash flow from operating